

# Eric T Wong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1011129/publications.pdf>

Version: 2024-02-01

96  
papers

7,917  
citations

136950

32  
h-index

69250

77  
g-index

99  
all docs

99  
docs citations

99  
times ranked

9280  
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1963-1972.	1.6	3,222
2	Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 1999, 17, 2572-2572.	1.6	850
3	NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. <i>European Journal of Cancer</i> , 2012, 48, 2192-2202.	2.8	661
4	Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers. <i>Lung Cancer</i> , 2015, 88, 108-111.	2.0	369
5	The natural history of extracranial metastasis from glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 105, 261-273.	2.9	168
6	Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit. <i>PLoS ONE</i> , 2015, 10, e0125269.	2.5	154
7	Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. <i>Cancer</i> , 2004, 101, 139-145.	4.1	131
8	Bevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 403-407.	4.9	118
9	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 317-328.	2.9	107
10	The Role of Topotecan in the Treatment of Brain Metastases. <i>Oncologist</i> , 2004, 9, 68-79.	3.7	101
11	Bevacizumab Reverses Cerebral Radiation Necrosis. <i>Journal of Clinical Oncology</i> , 2008, 26, 5649-5650.	1.6	95
12	Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.014688.	3.8	89
13	Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100A's System Versus Best Physician's Choice Chemotherapy. <i>Seminars in Oncology</i> , 2014, 41, S25-S34.	2.2	80
14	Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma. <i>Seminars in Oncology</i> , 2014, 41, S1-S14.	2.2	79
15	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	7.0	79
16	The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. <i>Cell Reports</i> , 2018, 24, 973-986.e8.	6.4	79
17	Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 85-90.	0.8	76
18	Neurological presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients. <i>BMC Neurology</i> , 2016, 16, 9.	1.8	73

#	ARTICLE	IF	CITATIONS
19	The natural history of intravascular lymphomatosis. <i>Cancer Medicine</i> , 2014, 3, 1010-1024.	2.8	70
20	Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3Tesla. <i>NeuroImage</i> , 2014, 99, 256-268.	4.2	70
21	Melanoma brain metastasis: overview of current management and emerging targeted therapies. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1207-1215.	2.8	69
22	Antiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 515-522.	4.9	67
23	NovoTTF-100A: a new treatment modality for recurrent glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 895-899.	2.8	66
24	Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields. <i>Seminars in Oncology</i> , 2014, 41, S14-S24.	2.2	59
25	An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 8.	4.2	54
26	Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. <i>Cancer Medicine</i> , 2014, 3, 592-602.	2.8	53
27	Identification of a panel of genes as a prognostic biomarker for glioblastoma. <i>EBioMedicine</i> , 2018, 37, 68-77.	6.1	46
28	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. <i>Neuro-Oncology</i> , 2016, 18, 849-854.	1.2	45
29	Noninvasive Application of Alternating Electric Fields in Glioblastoma: A Fourth Cancer Treatment Modality. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 126-131.	3.8	39
30	Taming Glioblastoma: Targeting Angiogenesis. <i>Journal of Clinical Oncology</i> , 2007, 25, 4705-4706.	1.6	38
31	Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. <i>Cerebrospinal Fluid Research</i> , 2008, 5, 1.	0.5	36
32	Nucleolin Is a Functional Binding Protein for Salinomycin in Neuroblastoma Stem Cells. <i>Journal of the American Chemical Society</i> , 2019, 141, 3613-3622.	13.7	35
33	Response and progression in recurrent malignant glioma. <i>Neuro-Oncology</i> , 1999, 1, 282-288.	1.2	34
34	Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma. <i>Cancer Medicine</i> , 2017, 6, 1286-1300.	2.8	33
35	Rare Phenomenon of Extracranial Metastasis of Glioblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 4594-4595.	1.6	31
36	Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. <i>Melanoma Research</i> , 2014, 24, 120-130.	1.2	30

#	ARTICLE	IF	CITATIONS
37	Clinical benefit in recurrent glioblastoma from adjuvant Novo TTF $\hat{a}$ €100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. <i>Cancer Medicine</i> , 2015, 4, 383-391.	2.8	27
38	An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas. <i>Current Treatment Options in Oncology</i> , 2015, 16, 40.	3.0	24
39	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. <i>Oncotarget</i> , 2015, 6, 2709-2724.	1.8	24
40	Stereotactic radiosurgery for brain metastases from malignant melanoma. , 2015, 6, 355.		24
41	Computed modeling of alternating electric fields therapy for recurrent glioblastoma. <i>Cancer Medicine</i> , 2015, 4, 1697-1699.	2.8	23
42	Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection. <i>Journal of Oncology</i> , 2015, 2015, 1-13.	1.3	23
43	Management of Central Nervous System Lymphomas Using Monoclonal Antibodies: Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2005, 11, 7151s-7157s.	7.0	21
44	Superior semicircular canal dehiscence in East Asian women with osteoporosis. <i>BMC Ear, Nose and Throat Disorders</i> , 2012, 12, 8.	2.6	20
45	Tubulin's response to external electric fields by molecular dynamics simulations. <i>PLoS ONE</i> , 2018, 13, e0202141.	2.5	20
46	Skin toxicities associated with tumor treating fields: case based review. <i>Journal of Neuro-Oncology</i> , 2017, 135, 593-599.	2.9	19
47	Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations. <i>Expert Review of Medical Devices</i> , 2015, 12, 717-726.	2.8	18
48	Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. <i>BMC Cancer</i> , 2016, 16, 914.	2.6	18
49	Dexamethasoneâ€”Friend or Foe for Patients With Glioblastoma?. <i>JAMA Neurology</i> , 2019, 76, 247.	9.0	18
50	Cyberknife Radiosurgery for Basal Skull Plasmacytoma. <i>Journal of Neuroimaging</i> , 2006, 16, 361-363.	2.0	17
51	Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy. <i>Radiation Oncology</i> , 2015, 10, 245.	2.7	14
52	Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies. <i>Chinese Clinical Oncology</i> , 2020, 9, 204-204.	1.2	14
53	Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 125-133.	2.9	14
54	SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2016-2016.	1.6	14

#	ARTICLE	IF	CITATIONS
55	Tumor growth, invasion, and angiogenesis in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2006, 77, 295-296.	2.9	13
56	Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality. <i>Progress in Neurological Surgery</i> , 2018, 32, 180-195.	1.3	13
57	Meningeal Carcinomatosis in Lung Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2926-2927.	1.6	10
58	End-to-end workflow for finite element analysis of tumor treating fields in glioblastomas. <i>Physics in Medicine and Biology</i> , 2017, 62, 8264-8282.	3.0	10
59	Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. <i>Neurology</i> , 2005, 64, 934-934.	1.1	9
60	Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	9
61	The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	9
62	Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2015-2015.	1.6	9
63	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 679702.	2.8	8
64	Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1107-1114.	1.8	7
65	Resolution of Cystic Enhancement to Add-On Tumor Treating Electric Fields for Recurrent Glioblastoma after Incomplete Response to Bevacizumab. <i>Case Reports in Neurology</i> , 2014, 6, 109-115.	0.7	7
66	Unusual Locations for Lymphomas. <i>Journal of Clinical Oncology</i> , 2001, 19, 2960-2963.	1.6	6
67	Quantitative ultrasound of muscle can detect corticosteroid effects. <i>Clinical Neurophysiology</i> , 2019, 130, 1460-1464.	1.5	6
68	Treatment advances for glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1343-1345.	2.8	5
69	Matrix Metalloproteaseâ€™9 in Cerebrospinal Fluid Correlates with Disease Activity in Lymphomatous Meningitis. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 305-308.	1.4	4
70	Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study. <i>Advances in Radiation Oncology</i> , 2021, 6, 100716.	1.2	4
71	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2004-2004.	1.6	4
72	Response to: Comment on â€™Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastomaâ€™™. <i>British Journal of Cancer</i> , 2015, 113, 1633-1634.	6.4	3

#	ARTICLE	IF	CITATIONS
73	Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2041-2041.	1.6	3
74	Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2037-2037.	1.6	3
75	TTFIELDS Therapy. , 2016, , 243-256.		2
76	Survival benefit of tumor treating fields plus stereotactic radiosurgery for recurrent malignant gliomas.. Journal of Clinical Oncology, 2015, 33, e13036-e13036.	1.6	2
77	Insights from Computer Modeling: Analysis of Physical Characteristics of Glioblastoma in Patients Treated with Tumor-Treating Fields. , 2019, , 155-161.		2
78	A pancancer analysis of impact of <i>MDM2/MDM4</i> on immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2022, 40, 2630-2630.	1.6	2
79	Corrigendum to "Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100A, System Versus Best Physician's Choice Chemotherapy" [Seminars in Oncology, Vol 41, No 5, Suppl 6, October 2014, pp S25-S34]. Seminars in Oncology, 2015, 42, e56-e66.		1
80	Angiogenesis and Brain Tumors. , 2011, , 1151-1171.		1
81	NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data.. Journal of Clinical Oncology, 2014, 32, e13033-e13033.	1.6	1
82	Tumor-Treating Electric Fields for Glioblastoma. , 2016, , 213-224.		1
83	Reply to Dr. Beuchet. Journal of Neuro-Oncology, 2012, 109, 595-595.	2.9	0
84	Corrigendum to "Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields" Seminars in Oncology, Vol 41, No 5, Suppl 6, October 2014, pp S14-S24. Seminars in Oncology, 2015, 42, e44-e55.	2.2	0
85	Computer Simulation of Tumor Treating Fields. , 2016, , 41-54.		0
86	Response Pattern and Modeling of Tumor Treating Fields. , 2016, , 55-65.		0
87	Clinical Efficacy of Tumor Treating Fields for Recurrent Glioblastoma. , 2016, , 67-77.		0
88	Tumor Treating Fields Therapy for Newly Diagnosed Glioblastoma. , 2016, , 93-102.		0
89	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
90	Everolimus shortens survival of newly diagnosed glioblastoma patients. Journal of Neuro-Oncology, 2018, 140, 179-180.	2.9	0

#	ARTICLE	IF	CITATIONS
91	Rapid Progressive Glioblastoma despite Radiation in a Patient with Myelodysplastic Syndrome. Case Reports in Oncology, 2021, 14, 424-429.	0.7	0
92	Parkinsonism reversed from treatment of pineal non-germinomatous germ cell tumor. , 2021, 12, 237.		0
93	T-cell primary central nervous system lymphoma: A systematic literature analysis.. Journal of Clinical Oncology, 2014, 32, e13034-e13034.	1.6	0
94	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.. Journal of Clinical Oncology, 2014, 32, 2027-2027.	1.6	0
95	Primary spinal cord glioblastoma: A systematic review.. Journal of Clinical Oncology, 2014, 32, e13035-e13035.	1.6	0
96	Guidelines for Burr Hole Surgery in Combination With Tumor Treating Fields for Glioblastoma: A Computational Study on Dose Optimization and Array Layout Planning. Frontiers in Human Neuroscience, 0, 16, .	2.0	0